Northwire Canada EditionSaturday, July 11, 2026
Sign inSubscribe
Northwire
⌕
GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0%
Financings

Hydreight Technologies Closes Strategic Investment in Insu Therapeutics

By The Northwire Desk — AI Analysis Mar 13, 2026 · 16:15 NURS · 2.68 Hydreight Technologies Inc.
NURS · Price

Executive Summary

  • Hydreight Technologies closed a $300,000 strategic investment in Insu Therapeutics, acquiring 800,000 units at $0.375 per unit.
  • The consideration was split evenly between cash ($150,000) and Hydreight common shares (37,037 shares valued at $4.05 each).
  • Each unit includes one Insu common share and a warrant to purchase an additional Insu share at $1.00 for two years, giving Hydreight exclusive U.S. distribution rights to any peptide therapeutics developed using Insu’s buccal delivery platform.

Key Details

  • Transaction Structure: 800,000 units @ $0.375 per unit = $300,000 total consideration.
  • Payment Breakdown: 50% cash ($150,000) and 50% Hydreight common shares (37,037 shares at a deemed price of $4.05).
  • Unit Composition: Each unit = 1 Insu common share + 1 warrant to purchase an additional Insu share at $1.00 exercisable for two years.
  • Strategic Rationale: Provides Hydreight early exposure to peptide delivery technology and aligns with its national digital health & pharmacy platform strategy.
  • Exclusive Rights: Hydreight secured exclusive U.S. rights to distribute peptide therapeutics using Insu’s buccal delivery technology, contingent on regulatory approvals.
  • Insu Development Milestones: Completed animal studies for insulin; advancing semaglutide (Ozempic) program; targeting manufacturing partnership completion within 12 months and FDA submission for clinical study approval in early 2027.
  • Management Commentary: CEO Shane Madden highlighted disciplined capital allocation and the potential to enhance Hydreight’s infrastructure with innovative delivery solutions. Co‑Founder Dr. Anubhav Pratap‑Singh emphasized accelerated development via the FDA 505(b)(2) pathway.

Notable Quotes

“This investment allows us to explore a potentially important innovation in peptide delivery while maintaining disciplined capital allocation and focus on scaling our core platform.” – Shane Madden, CEO, Hydreight Technologies

“Our buccal delivery platform is designed to enable peptide medicines to be absorbed through the oral mucosa… leveraging the FDA's 505(b)(2) pathway to accelerate development timelines.” – Dr. Anubhav Pratap‑Singh, Co‑Founder, Insu Therapeutics

Read the original news release →

More from Hydreight Technologies Inc.

Jun 01, 2026 · 21:32

Hydreight's Q1 EBITDA Margin Expansion Validates Operating Leverage, But Valuation Premium Demands Flawless Execution

Earnings May 01, 2026 · 00:14

Victory Square Technologies Inc.

Earnings Apr 30, 2026 · 20:56

Hydreight Validates Profitability Model But Aggressive 2026 Guidance Looms

Earnings Mar 13, 2026 · 18:43

Hydreight closes acquisition of 800,000 Insu units

M&A / Property Mar 09, 2026 · 08:00

Hydreight Announces Normal Course Issuer Bid

Other Mar 05, 2026 · 17:42

Hydreight invests $300,000 in Insu Therapeutics

M&A / Property